SciQuest gives customers full control over chemical inventory with latest ERM upgrade
Used by eight out of the top 10 global pharmaceutical companies, ERM’s newest version includes the industry’s first triple federated search engine.
SciQuest, a leading provider of spend management solutions delivering value beyond savings, has released the latest version of Enterprise Reagent Manager (ERM), the only chemical inventory management software that gives researchers and scientists full and efficient control over research inventory from sourcing and purchase through tracking and disposal.
Used by eight out of the top 10 global pharmaceutical companies, ERM’s newest version includes the industry’s first triple federated search engine, complete with real-time material availability check from suppliers, which allows search across all internal and external sources simultaneously. Through this robust capability, users can now search chemicals by supplier, chemical structure or text description to better meet their research needs.
With near instant startup, ERM 9 is up to 90 percent faster than previous versions. The dynamic and responsive user interface contains one-click tiles for quick navigation to important tasks and status icons that remain with use and display user actions, like items adding to a shopping cart or requesting a container for use from inventory. With the most modern UI that SciQuest has ever developed, ERM is adapted for the tablets and workstations most widely used in today’s research environments.
In addition to the federated search, the ERM 9 upgrade includes the following features:
Held Cart: Allows administrators to control purchases of high cost and/or hazardous materials from non-authorized personnel
“Since ERM closely integrates with procurement, pharmaceutical manufacturers can control complex inventories with reduced general spend and disposal costs, optimized inventory use, and increased regulatory compliance while managing the risks associated with hazardous materials,” said Stephen Wiehe, president and CEO of SciQuest. “With the first and only triple federated search, ERM is so powerful that it even allows the user to start taking action or look up specific information on displayed results, while continuing to receive results for more applicable chemicals or building block compounds.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.